English
English

Making everyone happy with data, everyday!

Making everyone happy with data, everyday!

Making everyone happy with data, everyday!

Our sole purpose is to make data universally accessible to all

Our sole purpose is to make data universally accessible to all

Our sole purpose is to make data universally accessible to all

Our vision

We envision to be the global digital leader for a universal access to data and artificial intelligence in life sciences and our society.

Our mission

Our mission is to develop Constellab™, the open and full digital ecosystem to connect any data, artificial intelligence, scientists and people.

Our values

Sharing

We believe in collaboration for efficient and sustainable knowledge sharing. We promote open data to make knowledge accessible to everyone

Commitment and integrity

We are committed to building a world with ethical and responsible use of data and artificial intelligence

Pragmatism

We are user-centric, committed to democratize artificial intelligence and digital twins by making these technologies easy to use by people

Corporate Social Responsability

Education

Training of new young generations is at the heart of our values and priorities to make to democratization of AI

Environmental impact

Our technologies are designed to be green-computing compliant and reduce the carbon footprint of the digital

Open innovation

We are open-source for a universal access to data and reduce inequalities in new digital era

Employment growth

Gencovery put an importance to have huge economic and social impact by creating new employments and services

Our history and roadmap

A concept initiated by two founders

Gencovery emerged from an idea that has been maturing since 2013, based on a simple observation: developing a drug takes over 15 years, and from more than 10,000 molecules tested, only one becomes a drug. The data generated for the other 9,999 molecules largely remains untapped. Imagine an iceberg: we use less than 10% of the knowledge above the surface, while the remaining 90% represents a vast, unexplored world of information.


In 2019 following the hospitalization of a family member suffering from cancer, Adama realized that access to patient data (clinical data, real world data) was a major health issue. This data is a gold mine that would make it possible to revolutionize diagnostics and the personalization of therapeutic care. For this, an "easy-to-access" digital infrastructure was needed to streamline the access to this massive data in research, in clinical studies, production, therapeutic care and ultimately in the collection and transparent use of real world data.


Even if no one believed it was possible, Gencovery helped turn this dream into reality!


Gencovery's mission is to build the largest, most accessible digital infrastructure to make data universally accessible to scientists and people worldwide.


The name "Gencovery" is a fusion of "GENE" and "DISCOVERY."


Since the beginning, Gencovery is supported by BIOASTER, LifeHub Lyon and SATT PULSALYS. 

01
01
01

2020 - Foundation

Gencovery is founded by 2 research scientists in applied mathematics, graduates of Ecole Centrale de Nantes (Djomangan Adama OUATTARA, PhD) and Ecole polytechnique (Wassim ABOU-JAOUDE, PhD). Gencovery is supported by the Technology Research Institute BIOASTER. We are incubated by SATT PULSALYS and LifeHub Lyon (Bayer).

2020 - Foundation

Gencovery is founded by 2 research scientists in applied mathematics, graduates of Ecole Centrale de Nantes (Djomangan Adama OUATTARA, PhD) and Ecole polytechnique (Wassim ABOU-JAOUDE, PhD). Gencovery is supported by the Technology Research Institute BIOASTER. We are incubated by SATT PULSALYS and LifeHub Lyon (Bayer).

2020 - Foundation

Gencovery is founded by 2 research scientists in applied mathematics, graduates of Ecole Centrale de Nantes (Djomangan Adama OUATTARA, PhD) and Ecole polytechnique (Wassim ABOU-JAOUDE, PhD). Gencovery is supported by the Technology Research Institute BIOASTER. We are incubated by SATT PULSALYS and LifeHub Lyon (Bayer).

2021

  • Gencovery deployed a first prototype of its digital platform and secured an initial contract with BAYER in Lyon (France).


  • Constellab™ is used in research and development to enhance the knowledge of microorganisms biology by utilizing AI and digital twins to design safer and more effective crops protection products.

2021

  • Gencovery deployed a first prototype of its digital platform and secured an initial contract with BAYER in Lyon (France).


  • Constellab™ is used in research and development to enhance the knowledge of microorganisms biology by utilizing AI and digital twins to design safer and more effective crops protection products.

2021

  • Gencovery deployed a first prototype of its digital platform and secured an initial contract with BAYER in Lyon (France).


  • Constellab™ is used in research and development to enhance the knowledge of microorganisms biology by utilizing AI and digital twins to design safer and more effective crops protection products.

02
02
02
03
03
03

2022

  • Constellab™ is now available in the cloud of OVHcloud and is adopted by the biotech company Adisseo to develop new solutions to improve nutrition


  • Constellab™ Community platform is available to provide documentation on Constellab™ for better support of our clients.


  • Gencovery won the R&D Booster 2022 call. Gencovery, Greencell, and BIOASTER are partnering to develop second-generation digital twins to improve bioprocess reliability with AI


  • Success of the 1st edition of the Constellab Connect event focused on the Digital Modeling of Microbial Communities in Life Sciences and Healthcare

2022

  • Constellab™ is now available in the cloud of OVHcloud and is adopted by the biotech company Adisseo to develop new solutions to improve nutrition


  • Constellab™ Community platform is available to provide documentation on Constellab™ for better support of our clients.


  • Gencovery won the R&D Booster 2022 call. Gencovery, Greencell, and BIOASTER are partnering to develop second-generation digital twins to improve bioprocess reliability with AI


  • Success of the 1st edition of the Constellab Connect event focused on the Digital Modeling of Microbial Communities in Life Sciences and Healthcare

2022

  • Constellab™ is now available in the cloud of OVHcloud and is adopted by the biotech company Adisseo to develop new solutions to improve nutrition


  • Constellab™ Community platform is available to provide documentation on Constellab™ for better support of our clients.


  • Gencovery won the R&D Booster 2022 call. Gencovery, Greencell, and BIOASTER are partnering to develop second-generation digital twins to improve bioprocess reliability with AI


  • Success of the 1st edition of the Constellab Connect event focused on the Digital Modeling of Microbial Communities in Life Sciences and Healthcare

2023

  • Gencovery is launching Constellab™ version 1, which has received positive feedback from its users. The company has developed a strong customer-success process.


  • Constellab™ is now available in cloud of Microsoft AZURE and can be deployed on premises


  • Gencovery initiated strategic collaborations with

    • the engineering school SupBiotech to support the training of AI and bioinformatics

    • Institut Imagine (AP-HP, hospitals of Paris) to apply digital twins to understand the metabolic mechanisms of rare genetic diseases


  • Constellab™ now provides generative AI to speed-up data exploration and visualization


  • Gencovery is accelerating its go-to-market by deploying a strong and mature marketing and sales force


  • Success of the 2nd edition of the Constellab Connect event focused on Artificial Intelligence in Biotechnology and Healthcare

2023

  • Gencovery is launching Constellab™ version 1, which has received positive feedback from its users. The company has developed a strong customer-success process.


  • Constellab™ is now available in cloud of Microsoft AZURE and can be deployed on premises


  • Gencovery initiated strategic collaborations with

    • the engineering school SupBiotech to support the training of AI and bioinformatics

    • Institut Imagine (AP-HP, hospitals of Paris) to apply digital twins to understand the metabolic mechanisms of rare genetic diseases


  • Constellab™ now provides generative AI to speed-up data exploration and visualization


  • Gencovery is accelerating its go-to-market by deploying a strong and mature marketing and sales force


  • Success of the 2nd edition of the Constellab Connect event focused on Artificial Intelligence in Biotechnology and Healthcare

2023

  • Gencovery is launching Constellab™ version 1, which has received positive feedback from its users. The company has developed a strong customer-success process.


  • Constellab™ is now available in cloud of Microsoft AZURE and can be deployed on premises


  • Gencovery initiated strategic collaborations with

    • the engineering school SupBiotech to support the training of AI and bioinformatics

    • Institut Imagine (AP-HP, hospitals of Paris) to apply digital twins to understand the metabolic mechanisms of rare genetic diseases


  • Constellab™ now provides generative AI to speed-up data exploration and visualization


  • Gencovery is accelerating its go-to-market by deploying a strong and mature marketing and sales force


  • Success of the 2nd edition of the Constellab Connect event focused on Artificial Intelligence in Biotechnology and Healthcare

04
04
04
05
05
05

2024

  • Q2 2024: Co-organisation of the 8th Boston Biotech Summit (may 2025); Preparation of the expansion of Gencovery in the US (50% of the global market)


  • Q2 2024: Leadership of the data/AI working group in collaboration with AFSSI (130 CROs in France)


  • Q3 2024: Release of the Fair Open Access offer to build the largest open community in data science through the Constellab Community platform


  • Q3 2024: Launch of the 1st round of a crowdfunding (bridge) campaign. Goals exceeded by over 150% in just 5 months


  • Q3 2024: Success of the 3rd edition of the Constellab Connect event focused on the Interoperability of Real-World Data to Accelerate Innovation in Life Sciences and Therapeutic care.


  • Q4 2024: Launch of the 2nd round of the crowdfunding (bridge) campaign after the rapid success of the 1st round

2024

  • Q2 2024: Co-organisation of the 8th Boston Biotech Summit (may 2025); Preparation of the expansion of Gencovery in the US (50% of the global market)


  • Q2 2024: Leadership of the data/AI working group in collaboration with AFSSI (130 CROs in France)


  • Q3 2024: Release of the Fair Open Access offer to build the largest open community in data science through the Constellab Community platform


  • Q3 2024: Launch of the 1st round of a crowdfunding (bridge) campaign. Goals exceeded by over 150% in just 5 months


  • Q3 2024: Success of the 3rd edition of the Constellab Connect event focused on the Interoperability of Real-World Data to Accelerate Innovation in Life Sciences and Therapeutic care.


  • Q4 2024: Launch of the 2nd round of the crowdfunding (bridge) campaign after the rapid success of the 1st round

2024

  • Q2 2024: Co-organisation of the 8th Boston Biotech Summit (may 2025); Preparation of the expansion of Gencovery in the US (50% of the global market)


  • Q2 2024: Leadership of the data/AI working group in collaboration with AFSSI (130 CROs in France)


  • Q3 2024: Release of the Fair Open Access offer to build the largest open community in data science through the Constellab Community platform


  • Q3 2024: Launch of the 1st round of a crowdfunding (bridge) campaign. Goals exceeded by over 150% in just 5 months


  • Q3 2024: Success of the 3rd edition of the Constellab Connect event focused on the Interoperability of Real-World Data to Accelerate Innovation in Life Sciences and Therapeutic care.


  • Q4 2024: Launch of the 2nd round of the crowdfunding (bridge) campaign after the rapid success of the 1st round

2025-

  • Q1 2025: Creation of a Joint Laboratory with the Imagine Institute to apply Constellab and Gencovery's digital twin technologies to accelerate the diagnosis of rare diseases in children. This partnership will consolidate Constellab (algorithms/UX/design) so that it can be easily used in hospitals to serve patients


  • Q2 2025: Release the first R&D Assistant in Constellab™ (using Generative AI)


  • Q2 2025: Deployment of the "Global-Data Exchange Network" dedicated to life sciences and healthcare through the Constellab Community platform


  • Reach of the breakeven point by 2026

2025-

  • Q1 2025: Creation of a Joint Laboratory with the Imagine Institute to apply Constellab and Gencovery's digital twin technologies to accelerate the diagnosis of rare diseases in children. This partnership will consolidate Constellab (algorithms/UX/design) so that it can be easily used in hospitals to serve patients


  • Q2 2025: Release the first R&D Assistant in Constellab™ (using Generative AI)


  • Q2 2025: Deployment of the "Global-Data Exchange Network" dedicated to life sciences and healthcare through the Constellab Community platform


  • Reach of the breakeven point by 2026

2025-

  • Q1 2025: Creation of a Joint Laboratory with the Imagine Institute to apply Constellab and Gencovery's digital twin technologies to accelerate the diagnosis of rare diseases in children. This partnership will consolidate Constellab (algorithms/UX/design) so that it can be easily used in hospitals to serve patients


  • Q2 2025: Release the first R&D Assistant in Constellab™ (using Generative AI)


  • Q2 2025: Deployment of the "Global-Data Exchange Network" dedicated to life sciences and healthcare through the Constellab Community platform


  • Reach of the breakeven point by 2026

06
06
06